VIVUS, Inc. (Nasdaq: VVUS) announced positive results from a multicenter, placebo-controlled study, TA-501, designed to assess the efficacy of STENDRA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE